Innoviva Inventory Turnover Ratio 2006-2019 | INVA

Innoviva inventory turnover ratio from 2006 to 2019. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period.
Innoviva Inventory Turnover Ratio Historical Data
Date
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.170B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $353.719B 15.46
Roche Holding AG (RHHBY) Switzerland $281.610B 0.00
Merck (MRK) United States $193.391B 14.69
Novartis AG (NVS) Switzerland $191.686B 15.96
Pfizer (PFE) United States $186.623B 11.40
Novo Nordisk (NVO) Denmark $141.701B 24.33
Eli Lilly (LLY) United States $133.660B 23.12
Bristol-Myers Squibb (BMY) United States $125.360B 11.89
AstraZeneca (AZN) United Kingdom $115.367B 24.84
Sanofi (SNY) France $112.261B 13.34
AbbVie (ABBV) United States $108.343B 8.21
GlaxoSmithKline (GSK) United Kingdom $92.675B 11.75
Bayer (BAYRY) Germany $53.491B 7.71
H Lundbeck (HLUYY) Denmark $5.974B 10.38